Preclinical and limited clinical literature on BPC-157, a synthetic pentadecapeptide studied in wound healing and GI models.
Also called BPC-157, Body Protection Compound 157, pentadecapeptide
Sources: 12 new papers · 5 key papers · updated Oct 20, 2026
Unverified · drafted by AI from the sources cited below
The stable gastric pentadecapeptide BPC 157 is an antiulcer peptide.1
BPC 157 was previously employed in ulcerative colitis and multiple sclerosis trials.1 In experimental models, rats received BPC 157 medication at doses of 10 µg/kg or 10 ng/kg intraperitoneally, intragastrically, or topically.2 A single-patient case study utilized a regenerative protocol that included a daily oral enteric-coated peptide capsule containing 1000 mcg total of peptides, including BPC-157.3
A framework evaluating BPC-157 assessed 70 evidence units across 23 studies and found no lawful source for the compound.1 Furthermore, while experimental evidence suggests that BPC-157 may affect biological pathways, these processes have been demonstrated mainly in preclinical models and have not been directly established in patients.2
Analysis of a Randomized, Placebo-Controlled Trial Evaluating an Oral Nutraceutical Supplement and Topical Peptide Serum for Females with Self-Perceived Hair Thinning
SKIN The Journal of Cutaneous Medicine — Nestor M — Nov 2026
Patients Use Google to Ask Questions About the Structure, Function, and Risks of Peptide Use in Orthopaedic Surgery
Arthroscopy Sports Medicine and Rehabilitation — Obana K — Nov 2026
Real-World Use, Dosing, and Reported Side Effects of BPC-157 and TB-500 for Musculoskeletal Injury: An Analysis of Online Communities
Cassinat J — Nov 2026
Rising Documented Use of Unapproved BPC-157 and Associated Patient-Reported Outcomes Curated from Clinical Notes
Biology Methods and Protocols — Venkatakrishnan A — Nov 2026
Quality Attributes and Documentation of Research-Grade Synthetic Peptides: A Grey-Literature Overview and Comparative Category Review (BPC-157, TB-500, GHK-Cu, Retatrutide and Reconstitution Supplies)
Club A — Nov 2026
Investigational Peptides in Orthopaedic Practice: Evidence, Safety, and Patient Counseling for BPC-157, Thymosin Beta-4, and TB-500
Journal of the American Academy of Orthopaedic Surgeons — Tham A — Oct 2026
Regenerative peptides for inferior alveolar nerve injury: a narrative review
Frontiers in Dental Medicine — Froum S — Oct 2026
Possibilities for Cytoprotective Liver Therapy, Stable Gastric Pentadecapeptide BPC 157, and Standard Agents—A Narrative Review
Pharmaceuticals — Sever M — Oct 2026
Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases
Frontiers in Oral Health — Froum S — Sep 2026
The Five-Gate Framework: A Two-Axis Evidence-Governance Instrument for Peptide Therapeutics in Pre-Consensus Use. Specification, Calibration on an Approved Anchor, and an Applied Monograph on BPC-157
Stanley N — Sep 2026
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Frontiers in Pharmacology — Seiwerth S
51 citations · 2021 · among the most cited on BPC-157
BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment
Biomedicines — Gojković S
38 citations · 2021 · among the most cited on BPC-157
Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157
Biomedicines — Knežević M
36 citations · 2021 · among the most cited on BPC-157
Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats
Biomedicines — Knežević M
36 citations · 2021 · among the most cited on BPC-157
Robert’s Intragastric Alcohol-Induced Gastric Lesion Model as an Escalated General Peripheral and Central Syndrome, Counteracted by the Stable Gastric Pentadecapeptide BPC 157
Biomedicines — Gojković S
34 citations · 2021 · among the most cited on BPC-157
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.